中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 10
Oct.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(10): 2343-2347

Screening of differentially expressed circular RNAs in intrahepatic cholangiocarcinoma based on microarray technique and potential mechanism of circRNA_000585

DOI: 10.3969/j.issn.1001-5256.2021.10.017
  • 1.

    Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China

  • 2.

    Jiangxi Cancer Hospital, Nanchang 330029, China

Research funding:

Jiangxi Provincial Department of Science and Technology (20203BBGL73144)

  • Received Date: 2021-02-20
  • Accepted Date: 2021-03-08
  • Published Date: 2021-10-20
    Abstract
  •   Objective  To screen out and validate the abnormally expressed circular RNAs (circRNAs) in intrahepatic cholangiocarcinoma (iCCA) by comparing the circRNA microarray results of iCCA tissue and adjacent tissue, and to investigate their potential mechanism in iCCA.  Methods  Tumor tissue specimens were collected from three patients with iCCA who were admitted from July to December, 2019, and microarray hybridization was used to measure the differential expression of circRNAs between iCCA tissue and adjacent tissue. A total of 15 patients with iCCA who were treated during the same period of time were enrolled, and quantitative real-time PCR was used for validation of differentially expressed circRNAs. A bioinformatics analysis was performed to identify the downstream molecules of differentially expressed circRNAs, and quantitative real-time PCR was used for validation of potential molecules. The paired samples t-test was used for comparison of continuous data between groups, and the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups.  Results  With 1.5-fold as the cut-off value for differential expression, there were 171 upregulated circRNAs and 104 downregulated circRNAs in iCCA tissue compared with the adjacent tissue. With 3-fold as the cut-off value for differential expression, there were 10 upregulated circRNAs (circRNA_002172, circRNA_002144, circRNA_001588, circRNA_000166, circRNA_000585, circRNA_000167, circRNA_402608, circRNA_006853, circRNA_001589, and circRNA_008882) and 3 downregulated circRNAs (circRNA_406083, circRNA_104940, and circRNA_006349) compared with the adjacent tissue. Pathologically confirmed iCCA tissue samples and adjacent tissue samples were collected from 15 patients, and quantitative real-time PCR was used for the validation of differentially expressed circRNAs; the results showed that circRNA_000585 was significantly upregulated in iCCA tissue (t=3.607, P=0.003). Further bioinformatics analysis showed that circRNA_000585/miR-615-5p/AMOT/YAP might be the potential pathway involved in the pathogenesis of iCCA, and quantitative real-time PCR showed that for this pathway, miR-615-5p was significantly downregulated in iCCA (t=5.724, P < 0.001) and AMOT and YAP were significantly upregulated in iCCA (t=2.664 and 2.986, P=0.019 and 0.009 8).  Conclusion  Abnormal expression of various circRNAs is observed in iCCA, among which circRNA_000585 is significantly upregulated in iCCA and may play an important role in the pathogenesis of iCCA via the circRNA_000585/miR-615-5p/AMOT/YAP pathway.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    RIZVI S, KHAN SA, HALLEMEIER CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2): 95-111. DOI: 10.1038/nrclinonc.2017.157.
    [2]
    VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. DOI: 10.1056/NEJMoa0908721.
    [3]
    LABIB PL, GOODCHILD G, PEREIRA SP. Molecular pathogenesis of cholangiocarcinoma[J]. BMC Cancer, 2019, 19(1): 185. DOI: 10.1186/s12885-019-5391-0.
    [4]
    LI J, SUN D, PU W, et al. Circular RNAs in cancer: Biogenesis, function, and clinical significance[J]. Trends Cancer, 2020, 6(4): 319-336. DOI: 10.1016/j.trecan.2020.01.012.
    [5]
    JIANG XM, LI ZL, LI JL, et al. A novel prognostic biomarker for cholangiocarcinoma: circRNA Cdr1as[J]. Eur Rev Med Pharmacol Sci, 2018, 22(2): 365-371. DOI: 10.26355/eurrev_201801_14182.
    [6]
    LU Q, FANG T. Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma[J]. J Clin Lab Anal, 2020, 34(4): e23138. DOI: 10.1002/jcla.23138.
    [7]
    LI D, TANG Z, GAO Z, et al. Circular RNA CDR1as exerts oncogenic properties partially through regulating MicroRNA 641 in cholangiocarcinoma[J]. Mol Cell Biol, 2020, 40(15). DOI: 10.1128/MCB.00042-20.
    [8]
    LOUIS C, DESOTEUX M, COULOUARN C. Exosomal circRNAs: New players in the field of cholangiocarcinoma[J]. Clin Sci (Lond), 2019, 133(21): 2239-2244. DOI: 10.1042/CS20190940.
    [9]
    MOIRANGTHEM A, WANG X, YAN IK, et al. Network analyses- based identification of circular ribonucleic acid-related pathways in intrahepatic cholangiocarcinoma[J]. Tumour Biol, 2018, 40(9): 1010428318795761. DOI: 10.1177/1010428318795761.
    [10]
    WANG S, HU Y, LV X, et al. Circ-0000284 arouses malignant phenotype of cholangiocarcinoma cells and regulates the biological functions of peripheral cells through cellular communication[J]. Clin Sci (Lond), 2019, 133(18): 1935-1953. DOI: 10.1042/CS20190589.
    [11]
    XU Y, YAO Y, ZHONG X, et al. Downregulated circular RNA hsa_circ_0001649 regulates proliferation, migration and invasion in cholangiocarcinoma cells[J]. Biochem Biophys Res Commun, 2018, 496(2): 455-461. DOI: 10.1016/j.bbrc.2018.01.077.
    [12]
    XU Y, YAO Y, LIU Y, et al. Elevation of circular RNA circ_0005230 facilitates cell growth and metastasis via sponging miR-1238 and miR-1299 in cholangiocarcinoma[J]. Aging (Albany NY), 2019, 11(7): 1907-1917. DOI: 10.18632/aging.101872.
    [13]
    GUO S, XU X, OUYANG Y, et al. Microarray expression profile analysis of circular RNAs in pancreatic cancer[J]. Mol Med Rep, 2018, 17(6): 7661-7671. DOI: 10.3892/mmr.2018.8827.
    [14]
    MUMTAZ PT, TABAN Q, DAR MA, et al. Deep insights in circular RNAs: From biogenesis to therapeutics[J]. Biol Proced Online, 2020, 22: 10. DOI: 10.1186/s12575-020-00122-8.
    [15]
    SONG H, LIU Q, LIAO Q. Circular RNA and tumor microenvironment[J]. Cancer Cell Int, 2020, 20: 211. DOI: 10.1186/s12935-020-01301-z.
    [16]
    LIANG ZZ, GUO C, ZOU MM, et al. circRNA-miRNA-mRNA regulatory network in human lung cancer: An update[J]. Cancer Cell Int, 2020, 20: 173. DOI: 10.1186/s12935-020-01245-4.
    [17]
    GODÍNEZ-RUBÍ M, ORTUÑO-SAHAGÚN D. miR-615 fine-tunes growth and development and has a role in cancer and in neural repair[J]. Cells, 2020, 9(7): 1566. DOI: 10.3390/cells9071566.
    [18]
    HUANG T, ZHOU Y, ZHANG J, et al. The physiological role of Motin family and its dysregulation in tumorigenesis[J]. J Transl Med, 2018, 16(1): 98. DOI: 10.1186/s12967-018-1466-y.
    [19]
    HONG W. Angiomotin'g YAP into the nucleus for cell proliferation and cancer development[J]. Sci Signal, 2013, 6(291): pe27. DOI: 10.1126/scisignal.2004573.
    [20]
    LV M, SHEN Y, YANG J, et al. Angiomotin family members: Oncogenes or tumor suppressors?[J]. Int J Biol Sci, 2017, 13(6): 772-781. DOI: 10.7150/ijbs.19603.
    [21]
    POCATERRA A, ROMANI P, DUPONT S. YAP/TAZ functions and their regulation at a glance[J]. J Cell Sci, 2020, 133(2): jcs230425. DOI: 10.1242/jcs.230425.
    [22]
    MA S, MENG Z, CHEN R, et al. The hippo pathway: Biology and pathophysiology[J]. Annu Rev Biochem, 2019, 88: 577-604. DOI: 10.1146/annurev-biochem-013118-111829.
    [23]
    SHAO DD, XUE W, KRALL EB, et al. KRAS and YAP1 converge to regulate EMT and tumor survival[J]. Cell, 2014, 158(1): 171-184. DOI: 10.1016/j.cell.2014.06.004.
    [24]
    YAMAGUCHI H, TAOUK GM. A potential role of YAP/TAZ in the interplay between metastasis and metabolic alterations[J]. Front Oncol, 2020, 10: 928. DOI: 10.3389/fonc.2020.00928.
    [25]
    MARTI P, STEIN C, BLUMER T, et al. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors[J]. Hepatology, 2015, 62(5): 1497-1510. DOI: 10.1002/hep.27992.
    [26]
    PARK J, KIM JS, NAHM JH, et al. WWC1 and NF2 prevent the development of intrahepatic cholangiocarcinoma by regulating YAP/TAZ activity through LATS in mice[J]. Mol Cells, 2020, 43(5): 491-499. DOI: 10.14348/molcells.2020.0093.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(8)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (474) PDF downloads(27) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return